| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045735464 |
| P356 | DOI | 10.1007/S00431-012-1758-9 |
| P698 | PubMed publication ID | 22652706 |
| P50 | author | Letizia Pomponia Brescia | Q42888536 |
| P2093 | author name string | Valerio Cecinati | |
| Fabio Giovanni Russo | |||
| Chiara Guastadisegni | |||
| P2860 | cites work | Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 |
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 | ||
| Pharmacology of itraconazole | Q32060460 | ||
| Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies | Q33392206 | ||
| Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America | Q33898624 | ||
| Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients | Q33938201 | ||
| Echinocandins: the newest class of antifungals | Q34019188 | ||
| Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. | Q34020746 | ||
| Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole | Q34095584 | ||
| Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents | Q34123805 | ||
| Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration | Q34141420 | ||
| Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children | Q34150923 | ||
| New targets and delivery systems for antifungal therapy | Q34154604 | ||
| Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections | Q34352100 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections | Q34481664 | ||
| Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? | Q34490092 | ||
| In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts | Q34680661 | ||
| Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections | Q34960317 | ||
| Efficacy and safety of itraconazole use in children | Q35211963 | ||
| Posaconazole plasma concentrations in juvenile patients with invasive fungal infection | Q35647678 | ||
| Clinical utility of antifungal pharmacokinetics and pharmacodynamics. | Q36004448 | ||
| New agents for invasive mycoses in children | Q36014270 | ||
| Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing | Q36094957 | ||
| Antifungal agents in children | Q36145061 | ||
| Antifungal treatment in pediatric patients | Q36212801 | ||
| Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial | Q46446545 | ||
| Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection | Q46486677 | ||
| Improved outcome in central nervous system aspergillosis, using voriconazole treatment | Q46585075 | ||
| Advances in antifungal therapy | Q46748490 | ||
| Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey | Q46907736 | ||
| Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis | Q46933151 | ||
| Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | Q51187346 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| Retrospective survey on the off-label use of posaconazole in pediatric hematology patients | Q60210851 | ||
| Pharmacokinetics of fluconazole in pediatric patients | Q72150369 | ||
| A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group | Q73165218 | ||
| Guidelines for treatment of candidiasis | Q75213797 | ||
| Caspofungin for the treatment of less common forms of invasive candidiasis | Q80385448 | ||
| Posaconazole | Q80403726 | ||
| Posaconazole: clinical pharmacology and potential for management of fungal infections | Q36233491 | ||
| Experience with caspofungin in the treatment of persistent fungemia in neonates | Q36285020 | ||
| Voriconazole therapy in children with cystic fibrosis | Q36293923 | ||
| Micafungin: a new echinocandin | Q36436847 | ||
| Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients | Q36593781 | ||
| Voriconazole : a review of its use in the management of invasive fungal infections | Q36729599 | ||
| Role of micafungin in the antifungal armamentarium | Q36822671 | ||
| Pharmacokinetics and safety of caspofungin in older infants and toddlers | Q37144851 | ||
| Posaconazole : a review of its use in the prophylaxis of invasive fungal infections | Q37154746 | ||
| Immunocompromised hosts: immunopharmacology of modern antifungals. | Q37186705 | ||
| Newer antifungal agents for invasive fungal infections in patients with haematological malignancy | Q37361400 | ||
| Overview of antifungal agents | Q37449812 | ||
| Caspofungin: in pediatric patients with fungal infections. | Q37535951 | ||
| Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients | Q37535957 | ||
| Itraconazole treatment of nonmeningeal coccidioidomycosis in children: two case reports and review of the literature | Q37626405 | ||
| A clinical review of echinocandins in pediatric patients | Q37653647 | ||
| Candidemia in children | Q37761730 | ||
| Invasive aspergillosis in pediatric patients | Q37761731 | ||
| Update on antifungal agents for paediatric patients | Q37777197 | ||
| Echinocandin antifungal drugs in fungal infections: a comparison | Q37822777 | ||
| Potential for interactions between caspofungin and nelfinavir or rifampin | Q40288945 | ||
| A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. | Q40359965 | ||
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 | ||
| Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility | Q41708431 | ||
| Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development | Q41740968 | ||
| In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 | ||
| In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species | Q42078338 | ||
| Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy | Q42957193 | ||
| Posaconazole salvage treatment in paediatric patients: a multicentre survey | Q43056048 | ||
| Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis | Q43111770 | ||
| Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole | Q43290163 | ||
| Cyclophosphamide metabolism is affected by azole antifungals | Q43530745 | ||
| Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children | Q43989240 | ||
| Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. | Q44125116 | ||
| Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study | Q45141879 | ||
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| Caspofungin therapy of neonates with invasive candidiasis | Q45207584 | ||
| A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients | Q46103005 | ||
| Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis | Q46213118 | ||
| Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis | Q46265389 | ||
| Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases | Q46404978 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 437-446 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | European Journal of Pediatrics | Q15755736 |
| P1476 | title | Antifungal therapy in children: an update | |
| P478 | volume | 172 |
Search more.